Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zitux versus MabThera in chronic lymphocytic leukemia
IRCT201305296302N5Phase 3Completed
- Sponsor
- AryoGen Biopharma
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by AryoGen Biopharma. Started Aug 2013; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on IRCT201305296302N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201305296302N5.